RESUMO
Mycosis fungoides, a rare form of cutaneous T cell leukemia/lymphoma, is suspected of having a viral etiology on the basis of certain similarities to adult T cell leukemia, which is associated with human T cell leukemia/lymphoma virus type I (HTLV-I) infection. Cell lines were established from peripheral blood mononuclear cells (PBMC) of an HTLV-I-seronegative patient with mycosis fungoides. DNA hybridization analysis revealed the presence of HTLV-I-related sequences with unusual restriction endonuclease sites. Sequence analysis of subcloned fragments demonstrated the presence of a monoclonally integrated provirus with a 5.5-kilobase deletion involving large regions of gag and env and all of pol. Additional evidence for the presence of deleted proviruses was found by polymerase chain reaction (PCR) amplification of DNA from cutaneous lesions of five other HTLV-I-seronegative patients. The findings suggest that HTLV-I infection may be involved in the etiology of at least certain cases of mycosis fungoides.
Assuntos
Deleção Cromossômica , Genes Virais , Vírus Linfotrópico T Tipo 1 Humano/isolamento & purificação , Linfócitos/microbiologia , Micose Fungoide/microbiologia , Provírus/isolamento & purificação , Neoplasias Cutâneas/microbiologia , Pele/microbiologia , Sequência de Bases , DNA de Neoplasias/genética , DNA de Neoplasias/isolamento & purificação , DNA Viral/genética , DNA Viral/isolamento & purificação , Vírus Linfotrópico T Tipo 1 Humano/genética , Humanos , Dados de Sequência Molecular , Micose Fungoide/sangue , Sondas de Oligonucleotídeos , Reação em Cadeia da Polimerase , Provírus/genética , Mapeamento por Restrição , Homologia de Sequência do Ácido Nucleico , Neoplasias Cutâneas/sangueRESUMO
The presence and properties of serum autoantibodies against beta-adrenergic receptors in patients with idiopathic dilated cardiomyopathy were studied using synthetic peptides derived from the predicted sequences of the human beta-adrenergic receptors. Peptides corresponding to the sequences of the second extracellular loop of the human beta 1- and beta 2-adrenergic receptors were used as antigens in an enzyme immunoassay to screen sera from patients with dilated cardiomyopathy (n = 42), ischemic heart disease (n = 17), or healthy blood donors (n = 34). The sera of thirteen dilated cardiomyopathy patients, none of the ischemic heart disease patients, and four of the healthy controls monospecifically recognized the beta 1-peptide. Only affinity-purified antibodies of these patients had a inhibitory effect on radioligand binding to the beta 1 receptor of C6 rat glioma cells. They recognized the receptor protein by immunoblot and bound in situ to human myocardial tissue. We conclude that a subgroup of patients with idiopathic dilated cardiomyopathy have in their sera autoantibodies specifically directed against the second extracellular loop of the beta 1-adrenergic receptor. These antibodies could serve as a marker of an autoimmune response with physiological and/or pathological implications.
Assuntos
Autoanticorpos/imunologia , Doenças Autoimunes/imunologia , Cardiomiopatia Dilatada/imunologia , Epitopos/imunologia , Receptores Adrenérgicos beta/imunologia , Adulto , Idoso , Sequência de Aminoácidos , Afinidade de Anticorpos , Autoanticorpos/sangue , Feminino , Humanos , Técnicas Imunoenzimáticas , Masculino , Pessoa de Meia-Idade , Dados de Sequência Molecular , Receptores Adrenérgicos beta/químicaRESUMO
Herpes simplex virus type 1 (HSV-1) has been associated with the genesis of leukoplakias, epithelial atypia, and oral cancer. Tobacco habits, such as snuff dipping, are also definitely correlated with this type of lesion. The normal cytolytic HSV-1 infection can, after in vitro inactivation, transform cells. Extracts of snuff were prepared and assayed for their ability to inhibit HSV-1 replication. Plaque formation assays of HSV-1 in the presence of snuff extract showed that a reduced number of plaques was formed. Different batches of one brand of snuff were tested for inhibition of herpes simplex virus (HSV) production. More than 99% inhibition of 24-hr HSV production was obtained with undiluted batches. The 1:5 dilutions of snuff had an inhibitory effect of 85% and 1:25 dilutions, 39%. In agreement, the attachment of the virus to the host cell and penetration of the virus to the cell nuclei were found to be inhibited as was the synthesis of viral DNA. Nicotine had an inhibitory effect, while aromatic additions to snuff were found to have no major inhibitory effect on HSV replication. Snuff extracts were prepared from different brands of snuff reported to contain high and low quantities of tobacco-specific N-nitrosamines. Brands with reported high levels of tobacco-specific N-nitrosamines had significantly greater ability to inhibit HSV replication. In conclusion, this study has shown that extracts of snuff have inhibitory effects on the production of cytolytic HSV-1 infections. A chronic snuff dipper keeps tobacco in the mouth for the major part of the day. Thus, virus shed in the oral cavity in connection with a reactivated latent HSV-1 infection has great possibilities of being affected by snuff or derivatives of snuff. It is suggested that an interaction between tobacco products and HSV-1 might be involved in the development of dysplastic lesions in the oral cavity.
Assuntos
Replicação do DNA/efeitos dos fármacos , Nicotiana , Extratos Vegetais/farmacologia , Plantas Tóxicas , Simplexvirus/efeitos dos fármacos , Animais , Linhagem Celular , Chlorocebus aethiops , Rim , Nicotina/toxicidade , Nitrosaminas/toxicidade , Simplexvirus/genética , Replicação Viral/efeitos dos fármacosRESUMO
OBJECTIVES: To measure the prevalence of HIV-1 infection in different subgroups of blood donors and to identify groups at high risk of acquiring HIV-1. METHODS: Between March 1988 and April 1991 all blood donors at Ilembula Lutheran Hospital, Tanzania were asked about their age, marital status, home village and occupation, and tested for the presence of HIV antibodies using a first generation, whole virus lysate enzyme-linked immunosorbent assay (ELISA). Some negative (n = 265) and nearly all positive samples (439 out of 485) were subjected to confirmatory testing including recombinant and peptide-based ELISA and Western blot assays. RESULTS: A total of 3474 male and 1287 female blood donors were studied. The overall HIV-1 prevalences for men and women were 6.6 and 7.0%, respectively, with a higher prevalence in urban villages (13.6 and 15.0%, respectively), an intermediate prevalence in semi-urban villages (7.2 and 7.9%, respectively), and a lower prevalence in rural villages (3.7 and 3.0%, respectively). HIV-1 infection occurred mostly in men aged 20-44 and women aged 15-34 years. Urban donors, but not semi-urban and rural donors from the highlands, had a higher HIV-1 prevalence (21.4%) than the corresponding group from the lowlands (10.2%). Apart from area of residence, HIV-1 infection was found to be associated with occupation and marital status. There was an increase in HIV-1 prevalence, although not statistically significant, during the period studied. None of the blood donors were positive for HIV-2. CONCLUSIONS: Male and female donors from urban and semi-urban villages, non-farmers from urban villages, and unmarried donors were identified as high-risk groups, which is consistent with more extensive risk behaviour in urban communities. In addition to using an HIV test with high sensitivity, the importance of pre-donation selection of blood donors is stressed.
Assuntos
Doadores de Sangue/estatística & dados numéricos , Soroprevalência de HIV , HIV-1 , Sorodiagnóstico da AIDS , Adolescente , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Gravidez , População Rural/estatística & dados numéricos , Sensibilidade e Especificidade , População Suburbana/estatística & dados numéricos , Tanzânia/epidemiologia , População Urbana/estatística & dados numéricosRESUMO
OBJECTIVE: To determine the value of (combinations of) synthetic peptides representing immunodominant sites on HIV-1/HIV-2 transmembrane proteins for the detection and discrimination between HIV-1 and HIV-2 infection in various populations. DESIGN AND METHODS: Two 24-mer synthetic peptides derived from immunodominant sites on the HIV-1 and HIV-2 transmembrane proteins were used separately, in combination (env 1/2), and in combination with recombinant p24 (p24/env) in enzyme-linked immunosorbent assays. RESULTS: Positive reactions with env-1 were found in 150 out of 150 (100%) samples from Dutch AIDS patients, 60 out of 60 (100%) samples from Dutch homosexual men obtained 1 year after HIV-1-antibody seroconversion, 29 out of 30 (96.7%) samples from these men obtained at the time of HIV-1-antibody seroconversion, 40 out of 41 (97.6%) samples from East Africans with AIDS-related symptoms, and three out of 29 (10.3%) samples from West Africans with HIV-2 infection (including a sample from an individual infected with both HIV-1 and HIV-2). Positive reactions with env-2 in these study populations were 11 out of 150 (7.3%), nine out of 60 (15%), none out of 30 (0%), 25 out of 41 (60.9%) and 29 out of 29 (100%), respectively. In the samples with dual reactivity, true versus cross-reactivity could generally be differentiated on the basis of large differences in optical density values in the respective assays. All samples reacted positively with p24/env; 308 out of 310 (99.3%) were positive in the env 1/2 assay. Four East African samples that had negative or only weakly positive reactions with env-1 showed a noticeably stronger reaction with variant peptides derived from Central African isolate sequences. In all samples from HIV-1-infected Dutch homosexual men, the strongest signal was detected using the env-1 peptide sequence, which is derived from European and American isolates. CONCLUSIONS: Small peptide antigens may permit the detection of strain-specific antibodies, allowing serological characterization of HIV isolates.
Assuntos
Proteína gp41 do Envelope de HIV/genética , HIV-1/imunologia , África , Sequência de Aminoácidos , Variação Antigênica , Infecções por HIV/microbiologia , HIV-1/genética , HIV-2/genética , HIV-2/imunologia , Humanos , Masculino , Dados de Sequência Molecular , Peptídeos/síntese química , Peptídeos/genética , Peptídeos/imunologiaRESUMO
A novel immunoenzyme amplification technique has been evaluated in an ELISPOT assay for the detection of antigen-specific antibody-secreting cells (ASC) in monkeys. In this assay, mononuclear cells containing putative ASC are incubated for a few hours in antigen-coated wells. Following removal of the cells, zones of solid phase bound antibodies secreted by individual ASC are visualized in four consecutive steps. First, a primary biotinylated anti-immunoglobulin (Ig) reagent is added followed by enzyme-labelled avidin. The amplification procedure comprises the addition of biotinylated anti-enzyme antibodies in the third stage, followed by enzyme-conjugated avidin and substrate. When evaluated in a modified ELISPOT assay for the detection of simian B cells secreting antibodies to the envelope glycoprotein gp120 of the human immunodeficiency virus type 1 (HIV-1), this amplification procedure proved to be suitable even when using anti-human Ig antisera as primary antibody reagents. This development should be useful for other ELISPOT assays where species specific anti-Ig reagents are not always available and, most importantly, for enumerating cells producing immunoreactive substances in such minute amounts that they may escape detection by conventional ELISPOT assays. Furthermore, a functional simian HIV-specific ELISPOT assay could prove valuable for assessing the humoral immunogenicity of future candidate vaccines against the acquired immunodeficiency syndrome (AIDS).
Assuntos
Células Produtoras de Anticorpos/imunologia , Anticorpos Anti-HIV/imunologia , HIV-1/imunologia , Macaca fascicularis/imunologia , Animais , Técnicas Imunoenzimáticas , Isotipos de Imunoglobulinas/análiseRESUMO
Five mouse hybridomas which produce monoclonal antibodies against the p17 core protein of HIV-1 have been isolated. Cross-competition assays and mapping with synthetic peptides demonstrate that two closely related epitopes are identified by these antibodies. Directed against two neighbouring peptides at the carboxy-terminal end of the molecule, they can be used for the selective detection of p17 polypeptide in a viral extract or in an infected cell lysate by a solid-phase sandwich enzyme immunoassay.
Assuntos
Anticorpos Monoclonais/imunologia , Anticorpos Antivirais/imunologia , Antígenos HIV/análise , HIV-1/imunologia , Peptídeos/análise , Sequência de Aminoácidos , Animais , Anticorpos Monoclonais/biossíntese , Anticorpos Antivirais/biossíntese , Especificidade de Anticorpos , Western Blotting , Linhagem Celular , Ensaio de Imunoadsorção Enzimática , Epitopos/análise , Epitopos/imunologia , Antígenos HIV/síntese química , Antígenos HIV/imunologia , Soropositividade para HIV/imunologia , Humanos , Camundongos , Camundongos Endogâmicos BALB C , Dados de Sequência Molecular , Mapeamento de Peptídeos , Peptídeos/síntese química , Peptídeos/imunologia , Testes de Precipitina/métodos , Produtos do Gene gag do Vírus da Imunodeficiência HumanaRESUMO
BACKGROUND: Real-time monitoring of cytomegalovirus (CMV) infections in transplant patients demands a rapid and high-throughput CMV DNA quantification method. METHODS: TaqMan polymerase chain reaction assays based on CMV immediate early protein exon 4 and glycoprotein B were developed and were compared with a COBAS AMPLICOR CMV MONITOR (CMM) test for quantifying CMV DNA in peripheral blood leukocytes from seven stem cell transplant patients having received antiviral treatment. RESULTS: There was a good correlation between the TaqMan assays and the CMM test for CMV DNA quantification. The throughput of the TaqMan assays was, however, about 3 times higher than that of the CMM test. The CMV DNA dynamics patterns determined by the TaqMan polymerase chain reaction were well in line with the outcome of the antiviral therapy. CONCLUSIONS: The TaqMan assays may potentially serve as a useful tool for rapid quantification of CMV infections in stem cell transplant patients.
Assuntos
Sistemas Computacionais , Infecções por Citomegalovirus/virologia , Transplante de Células-Tronco Hematopoéticas , Monitorização Fisiológica/métodos , Reação em Cadeia da Polimerase/métodos , Complicações Pós-Operatórias , Antivirais/uso terapêutico , Citomegalovirus/genética , Infecções por Citomegalovirus/tratamento farmacológico , Infecções por Citomegalovirus/etiologia , DNA Viral/análise , Estudos de Avaliação como Assunto , Humanos , Doadores Vivos , Monitorização Fisiológica/normasRESUMO
We have analyzed the relation between intrapatient variabilities of the p17 gene and the location of known host p17 cytotoxic T lymphocyte (CTL) epitopes in five patients infected with human immunodeficiency virus type 1 (HIV-1). All patients were typed with respect to the human leukocyte antigen (HLA) class I type. One to seven previously fine-mapped p17 CTL epitopes corresponded to the HLA class I restriction elements of each patient. An average of 28+/-16% of the p17 gene of each patient encoded CTL epitopes corresponding to the HLA restriction elements of the host. Twenty full-length p17 gene clones were sequenced from each patient. The intrapatient homology between the p17 sequences ranged from 96.4 to 98.9%. The interpatient homology between the consensus sequences of each patient ranged from 83.1 to 91.6%. A total of 246 nucleotide differences within the 100 p17 clones was noted. Fifteen (16%) of 96 synonymous substitutions were found within host CTL epitopes, whereas 72 (48%) of 150 nonsynonymous nucleotide changes were found within CTL epitopes corresponding to the HLA restriction elements of the host (p < 0.0001; Fisher's exact test). Subsequently, variable residues indicating the evolution of at least two major p17 species (i.e., >20% of the clones) were determined to be more common at positions contained within these CTL epitopes (p < 0.01). The present data suggest that the evolution of the p17 gene is influenced by contact areas with the host HLA class I molecules.
Assuntos
Produtos do Gene gag/genética , Genes MHC Classe I , Variação Genética , Antígenos HIV/genética , HIV-1/genética , HIV-1/imunologia , Antígenos de Histocompatibilidade Classe I/metabolismo , Linfócitos T Citotóxicos/imunologia , Proteínas Virais , Adulto , Sequência de Bases , Clonagem Molecular , Sequência Consenso , Mapeamento de Epitopos , Epitopos , Produtos do Gene gag/química , Genes Virais/genética , Antígenos HIV/química , Infecções por HIV/virologia , HIV-1/química , Antígenos de Histocompatibilidade Classe I/genética , Humanos , Masculino , Pessoa de Meia-Idade , Mutação , Filogenia , Reação em Cadeia da Polimerase , Análise de Sequência , Especificidade da Espécie , Produtos do Gene gag do Vírus da Imunodeficiência HumanaRESUMO
Transcription of the HIV-1 provirus genome is regulated by a complex interplay between viral regulatory proteins and cellular transcription factors that interact with the viral long terminal repeat (LTR) region of HIV-1. However, several cellular transcription factors have been identified that can interact with the HIV-1 LTR; the significance of all of these factors is not clearly understood. In this study we have characterized the LTR region of different subtypes of HIV-1 with regard to nucleotide sequence and promoter activity. The LTR regions of HIV-1 from peripheral blood mononuclear cells of 29 infected individuals originating from 10 different geographical regions were sequenced and further analyzed for promoter/enhancer activity in transient transfection of HeLa cells, in the context of a reporter gene and in the context of the complete virus genome. We found several subtype-specific LTR sequences of the various HIV-1 strains, such as an insertion that created a potential third NF-kappaB site in the LTR of the subtype C strains. The USF-binding site in the NRE also contained subtype-specific sequences. Interestingly, the promoter/enhancer activities of the subtype C LTRs were higher than the activities of the other subtypes analyzed here (subtypes A, B, D, E, and G), suggesting that the potential third NF-kappaB site may confer higher LTR activity or that the subtype C NRE may be less potent. Thus, our data suggest that genetic diversity of the LTR may result in HIV-1 subtypes with different replicative properties.
Assuntos
Ampliador HIV/genética , Infecções por HIV/genética , Repetição Terminal Longa de HIV/genética , HIV-1/genética , Regiões Promotoras Genéticas/genética , Adulto , África/etnologia , Sequência de Bases , Sítios de Ligação , Cloranfenicol O-Acetiltransferase , Ensaio de Imunoadsorção Enzimática , Feminino , Proteína do Núcleo p24 do HIV/metabolismo , Infecções por HIV/etnologia , Células HeLa , Humanos , Masculino , Pessoa de Meia-Idade , Dados de Sequência Molecular , NF-kappa B/metabolismo , Reação em Cadeia da Polimerase , Alinhamento de Sequência , Suécia/etnologia , TransfecçãoRESUMO
The HIV-1 long terminal repeat (LTR) promotes and modulates proviral transcription in the infected cell. It has been suggested that truncations and even point mutations in functional sites of the LTR are associated with low viral replication and attenuated pathogenesis in HIV-1-infected long-term nonprogressors (LTNPs). We performed a detailed analysis of LTR sequences from proviral DNA of 21 Italian and Swedish, well-characterized LTNPs and of 15 progressor patients. No truncation was found and no correlation was identified between specific LTR mutations and disease progression. We also failed to find a significant correlation between phylogenetic distance and clinical status. Although HIV-1 LTR interpatient heterogeneity among LTNPs and subjects with HIV-1 RNA levels <500 copies/ml tended to be lower, no sequence mutation was correlated with in vivo viral loads. Our results suggest that HIV-1 LTR defects are rare among Italian and Swedish LTNPs.
Assuntos
Infecções por HIV/virologia , Repetição Terminal Longa de HIV/genética , Sobreviventes de Longo Prazo ao HIV , HIV-1/fisiologia , Replicação Viral , Adolescente , Adulto , Sequência de Bases , DNA Viral/química , DNA Viral/genética , Europa (Continente) , Feminino , Infecções por HIV/epidemiologia , Infecções por HIV/imunologia , HIV-1/genética , HIV-1/isolamento & purificação , Humanos , Masculino , Pessoa de Meia-Idade , Dados de Sequência Molecular , Filogenia , RNA Viral/sangue , Análise de Sequência de DNARESUMO
A study by Hall et al. (J Virol 1992;66:2456-2463; Ref. 11) has suggested the existence of two closely related molecular subtypes of HTLV-II, which were tentatively designated HTLV-IIa and HTLV-IIb. To confirm this nucleotide sequence analysis of 986 bp of the env gene region encoding the entire surface glycoprotein, gp46, and the amino terminus of the transmembrane glycoprotein, gp21, of 10 HTLV-II isolates was carried out. The results clearly established the existence of two subtypes and demonstrated a 4.3% divergence in sequence in this region. Analysis of other gene regions of the provirus, including the pol (1544 bp), gag (448 bp), and the entire LTR (743 bp) of two representative isolates of each subtype, showed a sequence divergence of 3.8 to 5.7%, with greatest divergence occurring in the LTR. In addition to single nucleotide changes, the gag regions encoding the structural protein, p19, of the HTLV-IIb isolates were also found to have a 66-bp deletion that would be expected to result in a p19 protein having a 22-amino acid deletion in the carboxy-terminus region. Attempts to exploit this to differentiate the two subtypes serologically were unsuccessful in that recombinant p19 proteins of both subtypes were found to be antigenically cross-reactive. The finding of two molecular subtypes of HTLV-II may have important implications for a better understanding of the biological and pathogenic properties of the virus, and will be useful in characterizing the viruses present in endemic foci in American Indian populations.
Assuntos
Vírus Linfotrópico T Tipo 2 Humano/genética , Sequência de Aminoácidos , Sequência de Bases , DNA Viral , Produtos do Gene env/genética , Produtos do Gene gag/genética , Genes env , Genes gag , Genes pol , Antígenos HTLV-II/genética , Humanos , Dados de Sequência Molecular , Sequências Repetitivas de Ácido Nucleico , Proteínas Oncogênicas de Retroviridae/genética , Produtos do Gene env do Vírus da Imunodeficiência Humana , Produtos do Gene gag do Vírus da Imunodeficiência HumanaRESUMO
The humoral immune response in sera from 30 human T cell lymphotropic virus type I (HTLV-I)-positive individuals from Martinique in the French West Indies was studied. The subjects were subdivided into those suffering from TSP/HAM and those being asymptomatic. In general, TSP/HAM patient sera seemed to contain more virus-specific antibodies than did the sera from the asymptomatic subjects. Three of the 13 TSP/HAM sera and 1 of the 17 asymptomatic sera contained HTLV-I-specific IgM antibodies, whereas 6 and 5 sera, respectively, contained IgA antibodies. By correlating the ability of patient sera to inhibit HTLV-I-induced syncytia with their antibody reactivity in ELISA to 42 synthetic peptides, together corresponding to the entire envelope glycoprotein of HTLV-I, a number of putative neutralizing domains were identified. Eight synthetic peptides representing the regions with the highest coefficient of correlation between neutralizing titer and ELISA reactivity were employed to specifically adsorb potentially neutralizing antibodies, and were also used directly, without sera, in the syncytium-neutralizing test. By those techniques, three novel and two previously described domains that seemed to contain neutralizing epitopes were identified. Two of the novel neutralizing sites resided in the external glycoprotein (gp46) and were contained within amino acids 53-75 and 287-311, respectively, and one was located in the transmembrane glycoprotein (gp21) within amino acids 346-368. Our findings may have implications for the rational design of subunit vaccines for prevention of and/or alteration of the clinical outcome of HTLV-I-related diseases.
Assuntos
Produtos do Gene env/imunologia , Glicoproteínas/imunologia , Anticorpos Anti-HTLV-I/imunologia , Infecções por HTLV-I/imunologia , Vírus Linfotrópico T Tipo 1 Humano/imunologia , Proteínas Oncogênicas de Retroviridae/imunologia , Adulto , Idoso , Sequência de Aminoácidos , Ensaio de Imunoadsorção Enzimática , Feminino , Células Gigantes/citologia , Infecções por HTLV-I/sangue , Humanos , Masculino , Pessoa de Meia-Idade , Dados de Sequência Molecular , Testes de Neutralização , Peptídeos/síntese química , Peptídeos/imunologia , Produtos do Gene env do Vírus da Imunodeficiência HumanaRESUMO
The three amino acids glycine, proline, and glycine (GPG) constitute a conserved motif at the center of the V3 loop of HIV-1 surface glycoprotein 120. It has been indicated that deletion of this GPG motif is lethal for viral infectivity and abrogates the ability of the virus to form syncytia. In the present work, we studied the effects of GPG deletion on viral infectivity, cell tropism, syncytium formation, and initiation of apoptosis by constructing a mutant provirus based on the infectious clone pBRu-2. Successful infection and replication of GPG-deleted virus were detected in MT-2 cells, although the mutant virus showed lower infectivity. Infection could also be observed in the C8166, C91-PL, Molt-3, and THP-1 cell lines, and in PBMC-derived dendritic cells (DCs), but not in CEM-SS, HUT78, H9, Jurkat, and U937 cell lines or in PBMCs. Mutant virus also induced syncytia and apoptosis in the MT-2 cells. An intact GPG motif is probably necessary for unimpaired induction of fusion in some HIV-1-permissive cells. However, once the virus enters the cells, the GPG sequence does not seem to be indispensable for syncytium formation or apoptosis induction in MT-2 cells. Our data also imply that cell surface molecules other than CD4 and CXCR4 may be involved in entry of the GPG-deleted virus.
Assuntos
Proteína gp120 do Envelope de HIV/fisiologia , HIV-1/fisiologia , Fragmentos de Peptídeos/fisiologia , Motivos de Aminoácidos , Apoptose , Sítios de Ligação , Linhagem Celular , Glicina , Proteína gp120 do Envelope de HIV/genética , HIV-1/genética , Humanos , Células Jurkat , Fragmentos de Peptídeos/genética , Prolina , Deleção de Sequência , Células U937RESUMO
A new approach to detect and enumerate HIV-specific antibody-secreting cells (ASC) in the peripheral blood was developed using the enzyme-linked immunospot (ELISPOT) methodology. ASC to an HIV envelope recombinant protein were demonstrated in 75% of 16 adults and 72% of 21 children with untreated AIDS or ARC and in 63% of 34 asymptomatically infected adults but in none of the 51 HIV antibody-negative individuals. Only 1 of the 13 adults receiving AZT therapy yielded a positive reaction, and 27% of the 30 infants born to seropositive mothers were found to have HIV-ASC. The number of HIV-ASC in positive individuals varied from 8 to 202 per 10(6) circulating mononuclear cells. The reactivity was specifically inhibited by soluble HIV antigen and was abrogated by cycloheximide, indicating that the observed reaction was the result of de novo synthesis of HIV-specific antibodies. Nonspecific polyclonal B cell activation was unlikely to be responsible for the results observed as no reactivity was found to a common antigen, tetanus toxoid. Since circulating antigen-specific ASC reflect persistent or recent antigenic stimulation, our findings indicate that this new approach could provide a dynamic perspective of the natural course of virus-immune system interactions in individuals infected with HIV, as well as in those undergoing prophylactic or therapeutic interventions.
Assuntos
Complexo Relacionado com a AIDS/diagnóstico , Síndrome da Imunodeficiência Adquirida/diagnóstico , Células Produtoras de Anticorpos , Ensaio de Imunoadsorção Enzimática/métodos , HIV/imunologia , Complexo Relacionado com a AIDS/prevenção & controle , Síndrome da Imunodeficiência Adquirida/prevenção & controle , Pré-Escolar , Feminino , Seguimentos , Anticorpos Anti-HIV/biossíntese , Humanos , Lactente , Leucócitos Mononucleares/imunologia , Leucócitos Mononucleares/microbiologia , GravidezRESUMO
Monkey-derived hyperimmune antisera against 40 peptides, together representing the entire envelope gp120 of HIV-1LAI, were used to map antibody-dependent cellular cytotoxicity (ADCC) target regions. Four regions corresponding to amino acids 65-126, 152-230, 248-330, and 445-466 were found to contain epitopes inducing ADCC activity not only against HIV-1LAI-infected cells but also against cells infected with HIV-1SF2 and clinical isolates of HIV-1. When comparing seroreactivity to the individual peptides with ADCC titers none of the regions seemed to be dominant. These results thus describe cross-reactive regions involved in the functional immunity against HIV-1 gp120.
Assuntos
Especificidade de Anticorpos/imunologia , Epitopos de Linfócito T/imunologia , Anticorpos Anti-HIV/imunologia , Antígenos HIV/imunologia , Proteína gp120 do Envelope de HIV/imunologia , Infecções por HIV/imunologia , HIV-1/imunologia , Linfócitos T Citotóxicos/imunologia , Sequência de Aminoácidos , Animais , Reações Cruzadas , Infecções por HIV/sangue , Macaca fascicularis , Dados de Sequência Molecular , Células Tumorais CultivadasRESUMO
A multiple competitor PCR (mcPCR) was developed to quantify HIV-1 proviral DNA from peripheral blood mononuclear cells (PBMC). DNA extracted from a mixture of HIV infected PBMC and four size-mutated DNA competitors were co-amplified. The Cy5-fluorescence labelled PCR products were denatured by heating, separated using an automated DNA sequencer and quantified by a fragment analysis computer software. An internal standard was generated by plotting the peak areas of the four competitors against their inputs. Based on the internal standard, HIV sample DNA was quantified by extrapolating the corresponding signal. The linear range of the mcPCR was three log wide and the quantitation limit was about 20 copies of HIV DNA/10(6) PBMC. Using the mcPCR, HIV DNA was quantified from 14 long-term non progressors (LTNP) and 14 patients with advanced disease. A significantly lower copy number of HIV DNA was obtained in the LTNP (p = 0.018). These data suggest that the mcPCR is sensitive, reliable and especially useful for HIV DNA quantification of a large number of clinical samples.
Assuntos
DNA Viral/sangue , Infecções por HIV/virologia , HIV-1/isolamento & purificação , Leucócitos Mononucleares/virologia , Reação em Cadeia da Polimerase , Provírus/isolamento & purificação , Carga Viral , Progressão da Doença , HIV-1/genética , Humanos , Provírus/genética , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , ViremiaRESUMO
Herpes simplex virus (HSV) virions and nucleocapsids were separated and purified by centrifugation in density gradient of polyvinylpyrrolidone-coated colloidal silica (Percoll). Virions and nucleocapsids banded at densities of 1.07 and 1.03 g/ml, respectively. The distribution in the gradient of virions and nucleocapsids suggested that particles were discriminated according to difference in size rather than in density. The reduction of cell proteins in preparations of purified virions was 1300--2100 times. The recovery of infective virus was approximately 30%.
Assuntos
Capsídeo/isolamento & purificação , Simplexvirus/isolamento & purificação , Proteínas Virais/isolamento & purificação , Vírion/isolamento & purificação , Animais , Linhagem Celular , Centrifugação com Gradiente de Concentração , Chlorocebus aethiops , Povidona , Dióxido de SilícioRESUMO
A neurological surveillance was combined with prospective recording of upper respiratory and gastrointestinal infections and serological diagnosis of five common viral infections in 60 benign multiple sclerosis patients, with a mean follow-up of 31 months. During 4-week at risk (AR) periods encompassing common infections, a significant excess of MS relapses was found in the AR period, with a relative risk of 1.3. A seasonal variation of the MS relapse rate was found with a minimum in summer. There was a significant correlation between the number of AR relapses and the number of common infections per month explaining the periannual distribution of relapses. The non-AR relapses showed no seasonal variation. There was a significant correlation between adenovirus CF titre rises associated with upper respiratory infections and the occurrence of a major MS relapse in the AR period (n = 7), while influenza infections were not followed by a major MS relapse (n = 6). Linear homologies have been demonstrated between adenovirus and basic myelin protein. The epidemiological approach is essential to our understanding of systemic antigens triggering multiple sclerosis activity.
Assuntos
Esclerose Múltipla/complicações , Viroses/complicações , Adulto , Feminino , Seguimentos , Humanos , Masculino , Esclerose Múltipla/epidemiologia , Estudos Prospectivos , Recidiva , Testes Sorológicos , Viroses/diagnóstico , Viroses/epidemiologiaRESUMO
Acyclovir treatment was used in a randomized, double-blind, placebo-controlled clinical trial with parallel groups to test the hypothesis that herpes virus infections are involved in the pathogenesis of multiple sclerosis (MS). Sixty patients with the relapsing-remitting form of MS were randomized to either oral treatment with 800 mg acyclovir or placebo tablets three times daily for 2 years. The clinical effect was investigated by an extensive test battery consisting of neurological examinations, neuro-ophthalmological and neuropsychological tests, and evoked potentials. Results were based on "intent-to-treat" data and the primary outcome measure was the exacerbation rate. In the acyclovir group (n = 30), 62 exacerbations were recorded during the treatment period, yielding an annual exacerbation rate of 1.03. The placebo group (n = 30) had 94 exacerbations and an annual exacerbation rate of 1.57. Thus, 34% fewer exacerbations were encountered during acyclovir treatment. This difference in exacerbation rate between the treatment groups was not significant (P = 0.083). However, this trend to a lower disease activity in acyclovir-treated patients was supported in subsequent data analysis. If the patients were grouped according to exacerbation frequencies, i.e. into low (0-2), medium (3-5) and high (6-8) rate groups, the difference between acyclovir and placebo treatment was significant (P = 0.017). Moreover, in a subgroup of the population with a duration of the disease of at least 2 years providing an exacerbation rate base-line before entry, individual differences in exacerbation rates were compared between the 2-year pre-study period and the study period in acyclovir-treated (n = 19) and placebo (n = 20) patients and acyclovir-treated patients showed a significant reduction of exacerbations (P = 0.024). Otherwise, neurological parameters were essentially unaffected by acyclovir treatment and there were no convincing signs of reduced neurological deterioration in the acyclovir group. This study indicates that acyclovir treatment might inhibit the triggering of MS exacerbations and thus suggests that acyclovir-susceptible viruses might be involved in the pathogenesis of MS. This possibility warrants further investigation.